Merkel Year in Review: SPACE trial (JAMA 18) – opioids NOT superior to NSAIDs for function or pain in OA & back pain. #ACR18 @RheumNow pic.twitter.com/jQgc1eR67E

— ǝlʇʇıɥʍ ɯɐs (@samwhittle) October 21, 2018

US can be used to reliably identify structural and inflammatory changes in knee OA – often earlier or better than plain radiography. https://t.co/MSp2QlqSFP @RheumNow #ACR18 #2909

— Dr. Rachel Tate (@uptoTate) October 24, 2018

Dr. Cush
abstract 428
Significant Pain Reduction with Oral Methotrexate in Knee Osteoarthritis; Results from a Randomised Controlled Phase III Trial of Treatment Effectiveness —improved pain but not clinically meaningful
#ACR18 @Rheumnowhttps://t.co/S9wHaKjDLB

— Suleman Bhana, MD (@DrBhana) October 24, 2018

Tanezumab sc (anti-nerve growth factor) interesting for OA knee and hip, but the added elective joint replacements without radiographic differences between groups remains unexplained. More safety data on the way #ACR18 ABSTL20 @RheumNow

— David Liew (@drdavidliew) October 23, 2018

LB abstract L03: Yazici et al. Phase 2b trial SM04690 infra-articular Wnt pathway Inhibitor for treatment of OA of the knee. Improvement in pain and function but not JSN. #ACR18 @RheumNow https://t.co/s8MjlqtIay

— Suleman Bhana, MD (@DrBhana) October 23, 2018

#SticklerSyndrome a defect in type 2 collagen. Develop #osteoarthritis by age 40, sometimes as teenagers. #GeneticMimicsOfRheumaticDisease #ACR18 @RheumNow pic.twitter.com/jAnadcqgwf

— Nicole Bitencourt (@NicoleBitencou5) October 23, 2018

Hyperuricemia may contribute to the development and progression of knee OA
Krasnokutsky S et al
Year in review – clinical #ACR18 @RheumNow

— D White (@WIRheum) October 21, 2018

Asymptotic hyperuricemia May not be asymptotic. There is a higher incidence of symptomatic knee OA. #ACR18 @RheumNow Abstract 1355 pic.twitter.com/05synqXDCT

— William Shergy (@WilliamShergy) October 22, 2018

#ACR18 Plenary II: #1816 Katz:
Important to note that cumulative incidence of TKR over 5 yrs was much higher in those who received arthroscopic intervention vs no surgical intervention. @RheumNow pic.twitter.com/XMQz1ch0tN

— ǝlʇʇıɥʍ ɯɐs (@samwhittle) October 22, 2018

YIR 2. Does hyperuricemia contribute to worsening of OA?

Design: Knee xrays at baseline and 24 months

More knee joint space narrowing with hyperuricemia >6.8

Still correlation, not causation, but intriguing finding. #ACR18 @RheumNow

— Dr. Paul Sufka (@psufka) October 21, 2018

Dr. Peter Merkel discussing Serum Urate level predict joint space narrowing in non gout patients with knee OA. A&R 6/2018. SUA 6.8 mg/dL cutoff for JSN. SUA a biomarker for OA? #ACR18 @RheumNow

— Suleman Bhana, MD (@DrBhana) October 21, 2018

Dr. Peter Merkel discussing: Arthrocentesis and Joint Injections in Patient receiving Direct oral anticoagulants (other than warfarin). Yui et al. May Chin Proc 8/2017. Retrospective study 1050 procedures. Results: no episodes of bleeding. #ACR18 @RheumNow

— Suleman Bhana, MD (@DrBhana) October 21, 2018

Curbside consult at #Acr18: is EHOA a more severe from of OA or a distinct diagnostic entity? High association w/ metabolic syndorme and ⬆️ inflamm markers ( CRP,sIL-2R) support the latter but no consensus to date. NO evidence of HCQ& bDMARDs efficacy in EHOA @RheumNow pic.twitter.com/CMA51cQ0JJ

— Olga Petryna (@DrPetryna) October 21, 2018

Merkel Year in Review: SPACE trial (JAMA 18) – opioids NOT superior to NSAIDs for function or pain in OA & back pain. #ACR18 @RheumNow pic.twitter.com/jQgc1eR67E

— ǝlʇʇıɥʍ ɯɐs (@samwhittle) October 21, 2018

I should have said: Hyperuricemia associated with the development and progression of knee OA
Krasnokutsky S et al
Year in review – clinical #ACR18 @RheumNow

— D White (@WIRheum) October 21, 2018